Pharma and biotech deals into Europe.

Every deal is announced. The people part is not.

Octagon has tracked 7 cross-border deals in pharma and biotech into Europe and the UK since September 2026. France, Belgium and Germany received the most.

7Deals tracked

DateBuyer and targetStageSigning to Day 100People

20 OctAmbrose HealthcaretoAM-Pharma B.V.deal page: Ambrose Healthcare acquires AM-PharmaCompleted
SigningDay 100
not stated
19 OctMerck KGaAtoSilence Therapeutics plc deal page: Merck KGaA agrees to acquire Silence TherapeuticsSigned
SigningDay 100
not stated
23 SepArcturus Therapeutics Holdings Inc.tomyNEO Therapeutics deal page: Arcturus Therapeutics agrees to acquire myNEOSigned
SigningDay 100
not stated
21 SepTelix Pharmaceuticals LimitedtoITM Isotope Technologies Munich SE deal page: Telix agrees to acquire ITMSigned
SigningDay 100
not stated
14 SepAbacus Medicine GrouptoDelfarma deal page: Abacus Medicine Group agrees to acquire DelfarmaSigned
SigningDay 100
not stated
9 SepRevvity, Inc.toHuman Cell Design deal page: Revvity agrees to acquire Human Cell DesignSigned
SigningDay 100
not stated
3 SepResonant Clinical SolutionstoCreapharm Bioservicesdeal page: Resonant Clinical Solutions acquires Creapharm BioservicesCompleted
SigningDay 100
not stated

Get the briefing

Deals into Europe lists public facts with their sources, checked every working day by Octagon Professionals International. Corrections go to info@octagon.nl and are made within one working day. How we track deals.

Enabling organisations to operate across borders with clarity, compliance, and trust.

All deals into Europe